Study Of Sunitinib In Combination With Cisplatin/Capecitabine Or Oxaliplatin/Capecitabine In Patients With Advanced Gastric Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

76

Participants

Timeline

Start Date

May 31, 2008

Primary Completion Date

August 31, 2010

Study Completion Date

December 31, 2011

Conditions
Stomach Neoplasms
Interventions
DRUG

capecitabine

Capecitabine is given orally at 1000mg/m\^2 twice a day for 14 days followed by 7 days of drug free period.

DRUG

oxaliplatin

Oxaliplatin is given 110mg/m\^2 through a vein on day 1 every 21 days. Each 21 day cycle is repeated until progression of disease or unacceptable toxicity is observed.

DRUG

sunitinib malate

sunitinib is given orally 25mg/day for 14 days followed by 7 days of drug free period.

DRUG

capecitabine

Capecitabine is given orally at 1000mg/m\^2 twice a day for 14 days followed by 7 days of drug free period.

DRUG

cisplatin

Cisplatin is given 80mg/m\^2 through a vein on day 1 every 21 days. Each 21 day cycle is repeated until progression of disease or unacceptable toxicity is observed.

DRUG

sunitinib malate

sunitinib is given orally 25mg/day for 14 days followed by 7 days of drug free period.

Trial Locations (3)

410-769

Pfizer Investigational Site, Goyang-si

463-707

Pfizer Investigational Site, Seongnam-si

110-744

Pfizer Investigational Site, Seoul

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT00555620 - Study Of Sunitinib In Combination With Cisplatin/Capecitabine Or Oxaliplatin/Capecitabine In Patients With Advanced Gastric Cancer | Biotech Hunter | Biotech Hunter